AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36244843 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight chimney (Group I)
Number of subjects: 90
Study 36244843 — intervention group
Group type: EXPERIMENTAL
Intervention: Angled chimney (Group II)
Number of subjects: 90
Study 33627624 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HD-tDCS
Number of subjects: 66
Study 33627624 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Conv-tDCS
Number of subjects: 66
Study 33627624 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 66
Study 33357231 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen (TAM) for 2 years
Number of subjects: 564
Study 33357231 — intervention group
Group type: COMPARATOR
Intervention: No systemic treatment
Number of subjects: 564
Study 33357231 — intervention group
Group type: EXPERIMENTAL
Intervention: High (≥ 50%) infiltration of TILs
Number of subjects: 564
Study 34937686 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 52
Study 34937686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 33370158 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game
Number of subjects: 300
Study 33370158 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent video game
Number of subjects: 300
Study 32736597 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg twice daily on day 1, followed by 200 mg twice daily on days 8, 15, and 22 for Group 1; 400 mg twice daily on day 1 followed by 200 mg twice daily for 5-7 days for Group 2)
Number of subjects: 2300
Study 32736597 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 2300
Study 35489301 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib
Number of subjects: 370
Study 35489301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 33863673 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' experiences in managing early trauma emergencies
Number of subjects: 7
Study 35960075 — intervention group
Group type: EXPERIMENTAL
Intervention: astragalus injection with chemotherapy regimen containing anthracycline epirubicin
Number of subjects: 248
Study 35960075 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy regimen containing anthracycline epirubicin
Number of subjects: 248
Study 32658264 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 2463
Study 32658264 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 2463
Study 32658264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2463
Study 32658264 — intervention group
Group type: COMPARATOR
Intervention: Abaloparatide, Teriparatide, Placebo
Number of subjects: 2463
Study 36333741 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible charrière‐4 feeding tube (group 1)
Number of subjects: 31
Study 36333741 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi‐rigid catheter (group 2)
Number of subjects: 31
Study 36333741 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 31
Study 34496844 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed models during the lecture
Number of subjects: 347
Study 34496844 — intervention group
Group type: COMPARATOR
Intervention: Control group (2D images only)
Number of subjects: 347
Study 35238652 — intervention group
Group type: EXPERIMENTAL
Intervention: MuIS+
Number of subjects: 70
Study 35238652 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical limb (SX)
Number of subjects: 70
Study 35238652 — intervention group
Group type: COMPARATOR
Intervention: Contralateral limb (CTRL)
Number of subjects: 70
Study 34029674 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology massage for 15 min, for two consecutive days
Number of subjects: 60
Study 34029674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 32789761 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dispensing clinical pharmacists integrated in primary care teams
Number of subjects: 388
Study 32789761 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 388
Study 32789761 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus
Number of subjects: 388
Study 36116675 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Conditioning (GC)
Number of subjects: 38
Study 36116675 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (SA)
Number of subjects: 38
Study 36116675 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful Gastric Conditioning (GC)
Number of subjects: 38
Study 33297739 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat condition (n=187)
Number of subjects: 309
Study 33297739 — intervention group
Group type: COMPARATOR
Intervention: No-Threat condition (n=122)
Number of subjects: 309
Study 33297739 — intervention group
Group type: EXPERIMENTAL
Intervention: High compassion
Number of subjects: 309
Study 33297739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low compassion
Number of subjects: 309
Study 34394243 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care based on the Neuman Systems Model
Number of subjects: 160
Study 34394243 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 160
Study 36106465 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat acclimation training (5 consecutive days of moderate-intensity cycling at 60 min·day‐1 at 50% peak power output in a hot environment of 34.9±0.7 °C and 53±4 % relative humidity)
Number of subjects: 8
Study 36106465 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat acclimation training
Number of subjects: 8
Study 36106465 — intervention group
Group type: COMPARATOR
Intervention: Temperate training environment (22.2±2.6 °C; 65±8 % relative humidity)
Number of subjects: 8
Study 32889792 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccine
Number of subjects: 106
Study 32889792 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted vaccine
Number of subjects: 106
Study 32452973 — intervention group
Group type: EXPERIMENTAL
Intervention: FC2 Female Condom with a silicone placebo vaginal ring
Number of subjects: 81
Study 32452973 — intervention group
Group type: COMPARATOR
Intervention: FC2 Female Condom without a silicone placebo vaginal ring
Number of subjects: 81
Study 32452973 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 81
Study 32452973 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety and tolerability assessment
Number of subjects: 81
Study 35149205 — intervention group
Group type: EXPERIMENTAL
Intervention: AYUSH‐64 (two tablets of 500 mg each, three times a day for 30 days)
Number of subjects: 80
Study 35149205 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 80
Study 35436944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-based contrast during hysterosalpingography (HSG)
Number of subjects: 930
Study 35436944 — intervention group
Group type: COMPARATOR
Intervention: Water-based contrast during hysterosalpingography (HSG)
Number of subjects: 930
Study 35436944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-based contrast during HSG
Number of subjects: 930
Study 35436944 — intervention group
Group type: COMPARATOR
Intervention: Water-based contrast during HSG
Number of subjects: 930
Study 34195865 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP1RA
Number of subjects: 948342
Study 34195865 — intervention group
Group type: COMPARATOR
Intervention: DPP4i
Number of subjects: 948342
Study 32074255 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant discontinuation
Number of subjects: 123
Study 36169439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser vitreolysis
Number of subjects: 8
Study 32451788 — intervention group
Group type: EXPERIMENTAL
Intervention: Footprints (Motivational Interviewing-based prevention program)
Number of subjects: 43
Study 32451788 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual waitlist control
Number of subjects: 43
Study 36083097 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient cervical ripening with a synthetic osmotic dilator
Number of subjects: 339
Study 36083097 — intervention group
Group type: COMPARATOR
Intervention: Inpatient cervical ripening with a synthetic osmotic dilator
Number of subjects: 339
Study 36083097 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient cervical ripening
Number of subjects: 339
Study 36083097 — intervention group
Group type: COMPARATOR
Intervention: Inpatient cervical ripening
Number of subjects: 339
Study 32378266 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power (50 W) radiofrequency applications
Number of subjects: 120
Study 32378266 — intervention group
Group type: COMPARATOR
Intervention: Conventional-power (25-40 W) radiofrequency applications
Number of subjects: 120
Study 36164014 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB) 200 mg QD for 24 weeks
Number of subjects: 100
Study 36164014 — intervention group
Group type: COMPARATOR
Intervention: Danazol (DAN) 600 mg QD for 24 weeks
Number of subjects: 100
Study 33611104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg daily (n = 261)
Number of subjects: 392
Study 33611104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 131)
Number of subjects: 392
Study 33350752 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 34
Study 33350752 — intervention group
Group type: COMPARATOR
Intervention: Control (no HCQ)
Number of subjects: 34
Study 33595256 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal-sparing ILM peeling (FS group)
Number of subjects: 34
Study 33595256 — intervention group
Group type: COMPARATOR
Intervention: Complete ILM peeling
Number of subjects: 34
Study 32603994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal instruction (EXP)
Number of subjects: 47
Study 32603994 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (CON)
Number of subjects: 47
Study 33567023 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry in fast mode (Group I)
Number of subjects: 30
Study 33567023 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry in expert mode (Group II)
Number of subjects: 30
Study 33567023 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry expert mode (fixation stability)
Number of subjects: 30
Study 33567023 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between macular sensitivity threshold and examination duration
Number of subjects: 30
Study 32520644 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min neuromuscular training (INT10, n = 175)
Number of subjects: 342
Study 32520644 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min neuromuscular training (INT20, n = 167)
Number of subjects: 342
Study 32520644 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min neuromuscular training (INT10)
Number of subjects: 342
Study 32520644 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min neuromuscular training (INT20)
Number of subjects: 342
Study 32520644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 342
Study 33459247 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl Jasmonate (MJ) treatment at 30 mM
Number of subjects: 3
Study 33459247 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl Jasmonate (MJ) treatment at 60 mM
Number of subjects: 3
Study 33459247 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl Jasmonate (MJ) treatment at 100 mM
Number of subjects: 3
Study 33459247 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mM MJ)
Number of subjects: 3
Study 32383636 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy (measured on a 10-point Likert-type scale)
Number of subjects: 196
Study 32383636 — intervention group
Group type: COMPARATOR
Intervention: Knowledge (evaluated through 11 true/false items)
Number of subjects: 196
Study 34606114 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose group (tetravalent measles-mumps-rubella-varicella vaccine)
Number of subjects: 5803
Study 34606114 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose group (monovalent varicella vaccine)
Number of subjects: 5803
Study 34606114 — intervention group
Group type: COMPARATOR
Intervention: Control group (two doses of measles-mumps-rubella vaccine)
Number of subjects: 5803
Study 33006001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance Spectroscopy (BIS) monitoring, lymphoedema education and support
Number of subjects: 20
Study 33006001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance Spectroscopy (BIS) monitoring
Number of subjects: 20
Study 33872815 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular flushing (FF) using a 17-G double lumen needle
Number of subjects: 206
Study 33872815 — intervention group
Group type: COMPARATOR
Intervention: Direct follicular aspiration using a 17-G single lumen needle
Number of subjects: 206
Study 36346534 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide (50 mg once daily, increased to 100 mg once daily at day 15)
Number of subjects: 307
Study 36346534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 36346534 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide
Number of subjects: 307
Study 32003644 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigonal Botulinum toxin‐A (BTX‐A) injections (240 U into the detrusor plus 60 U into the trigone)
Number of subjects: 0
Study 32003644 — intervention group
Group type: COMPARATOR
Intervention: Nontrigonal Botulinum toxin‐A (BTX‐A) injections (300 U into the detrusor sparing the trigone)
Number of subjects: 0
Study 32293523 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) 150 mg/day for 60 days
Number of subjects: 240
Study 32293523 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) 400 mg/day for 15 days
Number of subjects: 240
Study 32293523 — intervention group
Group type: COMPARATOR
Intervention: Benznidazole (BNZ) 300 mg/day for 60 days (comparator arm)
Number of subjects: 240
Study 35606139 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual community of practice (vCoP) intervention for 12 months
Number of subjects: 321
Study 35606139 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 321
Study 34776161 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual pelvic floor exercises
Number of subjects: 33
Study 34776161 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual pelvic floor exercises with ultrasonography guidance
Number of subjects: 33
Study 34776161 — intervention group
Group type: EXPERIMENTAL
Intervention: Group pelvic floor exercises
Number of subjects: 33
Study 34776161 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 33
Study 33181797 — intervention group
Group type: EXPERIMENTAL
Intervention: Swing shift (noon to midnight)
Number of subjects: 3532
Study 33181797 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend days
Number of subjects: 3532
Study 32127659 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome/methylome prediction (WGMP) using Bayes-B model with SNPs selected based on LD-pruning and 1% of methylation sites based on Bayesian ridge regression (BRR)
Number of subjects: 0
Study 32127659 — intervention group
Group type: COMPARATOR
Intervention: Whole-genome prediction (WGP) using SNP marker information only
Number of subjects: 0
Study 32127659 — intervention group
Group type: COMPARATOR
Intervention: Whole-methylome prediction (WMP) using methylation profiles only
Number of subjects: 0
Study 32127659 — intervention group
Group type: COMPARATOR
Intervention: Bayesian regression models studied: BRR, Bayes-A, Bayes-B, Bayes-C, Bayesian LASSO
Number of subjects: 0
Study 35267997 — intervention group
Group type: EXPERIMENTAL
Intervention: Written dietary advice for lowering LDL cholesterol
Number of subjects: 113
Study 35267997 — intervention group
Group type: COMPARATOR
Intervention: Control group (triglycerides advice)
Number of subjects: 113
Study 33252549 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 tablets of hydrocodone/acetaminophen 10 to 325 mg
Number of subjects: 111
Study 33252549 — intervention group
Group type: COMPARATOR
Intervention: 60 tablets of hydrocodone/acetaminophen 10 to 325 mg
Number of subjects: 111
Study 36138306 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 106
Study 36138306 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients (severe group)
Number of subjects: 106
Study 36138306 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with thrombotic events
Number of subjects: 106
Study 36138306 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF in COVID-19 patients
Number of subjects: 106
Study 33843675 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-green (500 nm) light therapy for SCD treatment
Number of subjects: 150
Study 33843675 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-green (500 nm) light therapy for aMCI treatment
Number of subjects: 150
Study 35181275 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) intervention integrated in electronic health records, activated for patients with elevated cholesterol levels.
Number of subjects: 500000
Study 35181275 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 500000
Study 34129743 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised exercise programme for the jaw and orofacial muscles and individualised oral hygiene programme
Number of subjects: 29
Study 32092113 — intervention group
Group type: COMPARATOR
Intervention: sensor-only CPR
Number of subjects: 292
Study 32092113 — intervention group
Group type: EXPERIMENTAL
Intervention: sensor-feedback CPR
Number of subjects: 292
Study 35964867 — intervention group
Group type: EXPERIMENTAL
Intervention: LARKSPUR intervention
Number of subjects: 90
Study 35964867 — intervention group
Group type: COMPARATOR
Intervention: Emotion reporting/attention control
Number of subjects: 90
Study 32759888 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated lateral recumbent position (head and chest elevated 30°)
Number of subjects: 90
Study 32759888 — intervention group
Group type: COMPARATOR
Intervention: Regular lateral recumbent position
Number of subjects: 90
Study 35849399 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Analgesia (OA)
Number of subjects: 76
Study 35849399 — intervention group
Group type: COMPARATOR
Intervention: Opioid-Free Analgesia (OFA)
Number of subjects: 76
Study 35849399 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OA and OFA
Number of subjects: 76
Study 32589670 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth foam roller (STH)
Number of subjects: 33
Study 32589670 — intervention group
Group type: EXPERIMENTAL
Intervention: Grid foam roller (GRID)
Number of subjects: 33
Study 32589670 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 33
Study 89344702 — intervention group
Group type: EXPERIMENTAL
Intervention: Three reduced doses of Merck Sharp and Dohme (MSD) H‐B Vax plasma derived vaccine (2 micrograms each) given intramuscularly at monthly intervals.
Number of subjects: 1207
Study 33573696 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilavembu Kudineer (60 Ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days)
Number of subjects: 120
Study 33573696 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaba Sura Kudineer (60 Ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days)
Number of subjects: 120
Study 33573696 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated Tea (Placebo - 60 Ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days)
Number of subjects: 120
Study 33573696 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilavembu Kudineer
Number of subjects: 120
Study 33573696 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaba Sura Kudineer
Number of subjects: 120
Study 33573696 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated Tea (Placebo)
Number of subjects: 120
Study 32424455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventral Mesh Rectopexy (VMR)
Number of subjects: 120
Study 32424455 — intervention group
Group type: COMPARATOR
Intervention: Pelvic Organ Prolapse Suspension (POPS)
Number of subjects: 120
Study 34714139 — intervention group
Group type: EXPERIMENTAL
Intervention: RI aqueous extract fluid of 1.78 mg/mL
Number of subjects: 30
Study 34714139 — intervention group
Group type: EXPERIMENTAL
Intervention: RI aqueous extract fluid of 2.66 mg/mL
Number of subjects: 30
Study 34714139 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plain water)
Number of subjects: 30
Study 34791548 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPSA + EMD
Number of subjects: 24
Study 34791548 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPSA + EMD + BS
Number of subjects: 24
Study 33852339 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitors (PARPi) - olaparib and talazoparib, provided in capsule form
Number of subjects: 28
Study 33147665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol disoxate gel (IngDsx, 0.018% for face/chest; 0.037% for scalp)
Number of subjects: 1242
Study 33147665 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1242
Study 34162825 — intervention group
Group type: EXPERIMENTAL
Intervention: General awareness of oral cancer
Number of subjects: 5727
Study 34162825 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of risk factors for oral cancer
Number of subjects: 5727
Study 34162825 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions
Number of subjects: 5727
Study 32992832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention and olive oil
Number of subjects: 104
Study 33918677 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive, low-level dietary exposure to domoic acid (less than 20 ppm)
Number of subjects: 500
Study 35908579 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT) in the morning (08:00)
Number of subjects: 15
Study 35908579 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT) in the afternoon (16:45)
Number of subjects: 15
Study 32841261 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6%
Number of subjects: 1041